Researchers at the University of Bonn and the Johannes Gutenberg University Mainz have shown that melanoma cells can acquire resistance to
adoptive T cell transfer therapies by dedifferentiating themselves to hide
antigens.1 The group now is trying to circumvent this resistance
mechanism and thinks doing so could improve treatment responses for current T
cell therapy protocols.
From mechanism to therapies
The key question is whether the
mechanism observed in the mouse model applies to melanoma patients who have
received adoptive cell transfer.
Lou, K.-J. SciBX 5(42); doi:10.1038/scibx.2012.1100
Published online Oct. 25, 2012
1. Landsberg, J. et al.
Nature; published online Oct. 10, 2012; doi:10.1038/nature11538
Contact: Thomas Tüting, University of Bonn, Bonn, Germany
2. Atkins, M.B. et al.
J. Clin. Oncol. 17, 2105-2116 (1999)
3. Hodi, F.S. et al. N.
Engl. J. Med. 363, 711-723 (2010)
4. Rosenberg, S.A. et al.
Clin. Cancer Res. 17, 4550-4557 (2011)
5. Rosenberg, S.A. Nat.
Rev. Clin. Oncol. 8, 577-585 (2011)
6. Tormo, D. et al.
Cancer Res. 66, 5427-5435 (2006)
7. Landsberg, J. et al.
Pigment Cell Melanoma Res. 23, 649-660 (2010)
8. Kohlmeyer, J. et al.
Cancer Res. 69, 6265-6274 (2009)
AND INSTITUTIONS MENTIONED
Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla.
Johannes Gutenberg University Mainz, Mainz, Germany
National Cancer Institute, Bethesda, Md.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
University Hospital Bonn, Bonn, Germany
University of Bonn, Bonn, Germany
University of California, Los Angeles David Geffen School
of Medicine, Los
The University of Texas MD Anderson Cancer Center, Houston, Texas